Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
ChemoCentryx Announces 2011 Fourth Quarter and Full Year Financial Results
Date:3/30/2012
8 and the ChemR23 research program in 2011.
Research and development expenses for the fourth quarter 2011 were $5.4 million compared to $8.1 million for the same period in 2010. Research and development expenses for the year ended December 31, 2011 were $28.4 million compared to $33.5 million in 2010. The decrease was primarily due to the completion of the Phase II clinical trial for CCX354 in 2011.
General and administrative expenses for the fourth quarter of 2011 were $1.9 million and the same for the comparable period in 2010. General and administrative expenses for the year ended December 31, 2011 were $7.6 million compared to $7.3 million for 2010.
Cash, cash equivalents and investments totaled $96.1 million at December 31, 2011, compared to $82.8 million at December 31, 2010.
2012 Financial OutlookProjected 2012 year-end cash, cash equivalents and investments is expected to be at least $115.0 million.
About ChemoCentryxChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282, GSK1605786 or GSK'786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated
'/>"/>
| SOURCE ChemoCentryx, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related medicine technology :
1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
(Date:5/22/2013)... Utah , May 22, 2013 Aribex, Inc., ... X-ray system, today introduced a new color option, black ... the U.S. dental and veterinary markets. The popular white ... last month will continue to be available and both ... dealers. (Photo: http://photos.prnewswire.com/prnh/20130522/CL19573 ) ...
(Date:5/22/2013)... May 22, 2013 Heska Corporation (NASDAQ: HSKA, "Heska" or ... products, announced today that the Company will present at the ... 2013 at the Le Parker Meridian hotel, 119 W. 56 ... . The presentation is scheduled to begin at 2:15 p.m. ... Heska Heska Corporation (NASDAQ: HSKA - ...
(Date:5/22/2013)... LAGUNA HILLS, Calif. , May 22, 2013 /PRNewswire/ ... is developing a medical device that will help alleviate ... preeclampsia. APT,s targeted apheresis cartridge is expected to be ... a leading cause of maternal and fetal death. ... in the United States . It ...
Breaking Medicine Technology:Aribex Unveils New Color of NOMAD Pro 2 2Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2... (Nasdaq: MYL ) today announced that its subsidiary Mylan ... mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, ... mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg, ... used in the treatment of hypertension. Caduet Tablets ...
... Dec. 1, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... that the first patient has been dosed in its ... clostridium histolyticum) for the treatment of idiopathic adhesive capsulitis ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) ...
Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 2Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 3Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 4Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 6(Date:5/22/2013)... The surging growth in specialty beds ... marketing claims to compare mattresses often proves a bit ... bed blog , offers shoppers faced with this dilemma ... latest article. , Titled “ Mattress Comparison Overview – ... readers through the basics of innerspring beds as well ...
(Date:5/22/2013)... Prairie, WI (PRWEB) May 23, 2013 ... , introduced a new feature to its website ... from the agency’s client portfolio through an immersive, 360-degree, ... clients and prospective customers the ability to virtually experience ... a developer of medical technologies and services. Users have ...
(Date:5/22/2013)... May 23, 2013 Existing research shows that bicyclists who ... brain injury, but researchers at Boston Children,s Hospital found ... a 20 percent decrease in deaths and injuries for ... vehicle collisions. , The cross-sectional study, conducted by ... MPH, Rebekah C. Mannix, MD, MPH of Boston Children,s ...
(Date:5/22/2013)... Textile Exchange, a non-profit organization ... industry, today released the 2011-12 Farm & Fiber ... production dropped 8% from last year. This drop ... drop in 2010-11. Half of the organic cotton-growing ... Textile Exchange’s seventh, provides unique data, trends and ...
(Date:5/22/2013)... San Francisco, CA (PRWEB) May 22, 2013 ... funerals costing $6,500 or more on average, a funeral concierge ... a funeral, among other benefits. Funeral Financials ... With the average household income in the U.S. ... recession according to Sentier Research, the average funeral costs 12.6% ...
Breaking Medicine News(10 mins):Health News:Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands 2Health News:Catalyst Exhibits Debuts 360 Degree Virtual Tour of St. Jude Medical Trade Show Booth 2Health News:Rate of bicycle-related fatalities significantly lower in states with helmet laws 2Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 2Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 3Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 4Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3[0] Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands[0] Catalyst Exhibits Debuts 360 Degree Virtual Tour of St. Jude Medical Trade Show Booth[0] Rate of bicycle-related fatalities significantly lower in states with helmet laws[0] Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report[0] Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge
... Calorie-conscious, health-minded,Americans who love to eat out ... in following,through with New Year,s resolutions. HealthyDiningFinder.com, ... at a growing number,of restaurants nationwide. More ... dining establishments currently participate. Site visitors "search",for ...
... Blades, Inc. and its,medical device division IncisionTech announced ... Sons, Inc. The acquisition of Popper, a leading,specialty ... the combined company the leading contract manufacturer of ... Specialty Blades,originally announced its intention to acquire Popper ...
... SAN FRANCISCO, Jan. 7 Hodge / Niederer / ... firm announced,today that Vicky Goldberg has joined as Partner. ... and will focus on the media, entertainment and,consumer sectors., ... President of Worldwide,Recruitment at Warner Bros. Entertainment, Inc. Before ...
... But those who bought from doctors checked their prescriptions, kept ... News) -- While buying contact lenses online may save time ... follow proper eye care, new research shows. , ... trouble down the line, warned the investigators, who found that ...
... The Columbia Center for Childrens Environmental Health ... Health, has received a $10.4 million grant from ... to study environmental contributors to childhood asthma. ... initiative called Disease Investigation through Specialized Clinically-Oriented Ventures ...
... children are able to imagine their future selves as ... find it difficult to recollect past events, let alone ... that the ability of older adults to form imaginary ... memories. , According to the study, episodic memory, which ...
Cached Medicine News:Health News:Online Resource Keeps Restaurant Diners on Track After New Year's Hype Subsides 2Health News:Vicky Goldberg Joins Executive and Board Search Firm Hodge / Niederer / Cariani / Lindsay 2Health News:Eye Care Lacking in Many Who Buy Contact Lenses Online 2Health News:Columbia Center for Children's Environmental Health receives NIEHS grant to study asthma 2Health News:Columbia Center for Children's Environmental Health receives NIEHS grant to study asthma 3Health News:Columbia Center for Children's Environmental Health receives NIEHS grant to study asthma 4Online Resource Keeps Restaurant Diners on Track After New Year's Hype SubsidesSpecialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.Vicky Goldberg Joins Executive and Board Search Firm Hodge / Niederer / Cariani / LindsayEye Care Lacking in Many Who Buy Contact Lenses OnlineColumbia Center for Children's Environmental Health receives NIEHS grant to study asthmaLack of imagination in older adults linked to declining memory
... 2.4mm channel within a 12.1mm insertion tube. ... linear array ultrasound image for improved reliability, ... resolution, and a 7.5 and 5.0mhz transducer ... & pulsed doppler allows for anatomical orientation ...
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... ACL 1000 is an affordable solution ... backup analyzer. The test menu includes a ... and APCR-V Leiden. The ACL 1000 also ... efficiency in your lab. Plus, it's backed ...
... takes the automation and versatility of ... the benefit of electrolyte testing. It's ... for the low- to medium-volume laboratory, ... continuous sample loading. The SYNCHRON CX5 ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |